Menu Search

CSL and HBM Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire

CSL Limited (ASX: CSL) and Vitaeris, a privately held company in the portfolio of HBM Healthcare Investments, today announced that they have entered into a strategic partnership to expedite development of clazakizumab (anti-IL6 Mab) as a therapeutic option for solid organ transplant rejection.